Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 13, 2021

View Archived Issues

mRNA vaccine can tamp down immunity, too

Amnion secretome neuroprotection takes all parts

M. tuberculosis-derived rRv-2626c-CA peptide protects mice from sepsis

Finerenone lowers risk of CKD progression and cardiovascular events in CKD with type 2 diabetes

Verve Therapeutics selects VERVE-101 as its lead gene editing therapy candidate

Initiation of pivotal global study evaluating CLR-131 in Waldenstrom's macroglobulinemia

Veralox submits IND to the FDA for VLX-1005

Dana-Farber Cancer Institute synthesizes new EGFR inhibitors

Pfizer and CTxT Pty divulge new KAT inhibitors

U.S. researchers disclose compounds for West Nile viral infection

Anti-CLDN18.2/CD47 antibodies presented by Phanes Therapeutics

Alzheimer's disease subtypes may explain, improve clinical results

Rezolute initiates first-in-human study of RZ-402

New adenosine A2A receptor antagonists presented by AMMS

Positive topline data from ongoing phase II LiFT study of LPCN-1144

Successful preclinical data for ImmCelz as treatment of stroke

Japanese phase III trial of AJM-300 in ulcerative colitis meets primary endpoint

Novel AAV gene therapy rescues hearing loss in Syne4-/- mice

Apabetalone protects from heart failure in patients with T2D and ACS

JD-1 preferentially targets cell membranes of Gram-negative bacteria

Dovobet Foam approved in Japan for psoriasis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...